<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03548675</url>
  </required_header>
  <id_info>
    <org_study_id>848016004</org_study_id>
    <nct_id>NCT03548675</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics Informed Tricyclic Antidepressant Dosing (PITA)</brief_title>
  <acronym>PITA</acronym>
  <official_title>Pharmacogenetics to Improve Personalized Antidepressant Dosing in Patients With Severe Depression;a Randomized Controlled Trial Using Tricyclic Antidepressants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tricyclic Antidepressants (TCA's) are the cornerstone of treatment for patients with severe&#xD;
      Major Depressive Disorder (sMDD). Current dosing is guided by repeated measurements of blood&#xD;
      levels. Compared to patients with a normal metabolization function, for those with increased&#xD;
      CYP450 enzyme activity it takes longer to reach a therapeutic drug level. The consequent&#xD;
      delay of drug efficacy is associated with a prolonged treatment period, increased risk of&#xD;
      suicidal behaviour and eventually lower remission rates. For those with reduced CYP450&#xD;
      activity higher rates of side effects are expected. An innovative TCA dosing strategy, taking&#xD;
      the genetic variants of CYP2D6 and CYP2C19 into account may help to reduce the above&#xD;
      mentioned problems. Up till now, the current guidelines for CYP450 pharmacogenetics based TCA&#xD;
      dosing have not been systematically evaluated for effectiveness and cost-effectiveness in&#xD;
      larger groups of patients. Such evaluation is necessary before broad implementation of these&#xD;
      guidelines can be advocated. In the present study 200 patients with sMDD who are treated with&#xD;
      nortriptyline, clomipramine or imipramine are randomized over two strategies: dosing based&#xD;
      both on CYP450-genotype and blood level measurements and dosing as usual (standard doses plus&#xD;
      blood levels). We hypothesize that genotype informed dosing results in faster attainment of&#xD;
      therapeutic drug levels, lower rates of side effects, earlier symptom relief and lower levels&#xD;
      of health- and working related costs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a randomized controlled clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Prescribing physicians will be unblinded for the genotype and the resulting metabolization phenotype. Outcome assessments will be performed by blinded researchers and the patients themselves (self-assessments).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to TCA plasma concentration in the therapeutic range</measure>
    <time_frame>During the 7 weeks treatment phase</time_frame>
    <description>Time to TCA plasma concentration in the therapeutic range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of depressive symptoms</measure>
    <time_frame>Difference between measurements at baseline and after 7 weeks of treatment</time_frame>
    <description>HAM-D reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest level of side effects</measure>
    <time_frame>During the 7 weeks treatment phase</time_frame>
    <description>summary measure: FIBSER</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic Evaluation (Cost Effectiveness)</measure>
    <time_frame>26 weeks after the start of treatment</time_frame>
    <description>Utility based on EQ5D5L measurement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Genotype-guided TCA treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype guided dosing of the TCAs in patients with a PM,IM,EM or UM phenotype based on pharmacogenetic test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard TCA treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dosing of TCA in patients with a PM,IM, EM or UM phenotype based on pharmacogenetic test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCA treatment</intervention_name>
    <description>All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).</description>
    <arm_group_label>Genotype-guided TCA treatment</arm_group_label>
    <arm_group_label>Standard TCA treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients are in- and outpatients, having a primary diagnosis of severe major depressive&#xD;
        disorder (SCID-I diagnosis in agreement with DSM-5 criteria and a Hamilton Rating Scale for&#xD;
        Depression score â‰¥ 19 (HAM-D-17-item version), aged 18-65 years, who, according to their&#xD;
        physician, are eligible for treatment with a TCA (Nortriptyline (NOR), Clomipramine (CLOMI)&#xD;
        or Imipramine (IMI)). The choice of the specific TCA is at the discretion of the physician&#xD;
        in attendance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Psychotic depression&#xD;
&#xD;
          2. Bipolar I or II disorder.&#xD;
&#xD;
          3. Schizophrenia or other primary psychotic disorder.&#xD;
&#xD;
          4. Drug or alcohol dependence in the past 3 months.&#xD;
&#xD;
          5. Mental Retardation (IQ &lt; 80).&#xD;
&#xD;
          6. For women: pregnancy or possibility for pregnancy without adequate contraceptive&#xD;
             measures.&#xD;
&#xD;
          7. Breastfeeding.&#xD;
&#xD;
          8. Serious medical illness affecting the CNS, including but not restricted to M&#xD;
             Parkinson, SLE, brain tumour, CVA.&#xD;
&#xD;
          9. Relevant medical illness as contra-indication for TCA use, such as recent myocardial&#xD;
             infarction.&#xD;
&#xD;
         10. Other drugs influencing the pharmacokinetics of the TCAs as based on a list of&#xD;
             interacting drugs. In case of psychotropic co-medication only a benzodiazepine in a&#xD;
             dose equivalent up to 4 mg lorazepam will be allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost Janzing, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboudumc dept of Psychiatry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joost Janzing, MD PhD</last_name>
    <phone>+31-(0)243613489</phone>
    <email>Joost.Janzing@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marieke Coenen, PhD</last_name>
    <phone>+31-(0)243617752</phone>
    <email>Marieke.Coenen@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboudumc Dept of Psychiatry</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joost Janzing, MD, PhD</last_name>
      <phone>0031243666495</phone>
      <email>Joost.janzing@radboudumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Antidepressive Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

